XERIS BIOPHARMA Reports Q2 Earnings Results for 2023
August 12, 2023
🌥️Earnings Overview
XERIS BIOPHARMA ($NASDAQ:XERS) announced its second quarter earnings for the period ending June 30, 2023, on August 8, 2023. Total revenue amounted to USD 38.0 million, a 50.2% increase from the same period in 2022. Net income was -19.8 million, improving from the -26.2 million reported last year.
Price History
On Tuesday, XERIS BIOPHARMA reported their earnings results for Q2 2023. The stock opened at $2.4 and closed at $2.6, representing a 3.6% increase from the previous closing price of $2.5. This surge in the stock price is an indication of the market’s optimism in XERIS BIOPHARMA’s ability to achieve and surpass its earnings targets for the quarter. This growth was largely attributed to the company’s robust portfolio of drugs, which performed well in the quarter and helped to drive up sales. The company also announced that it would be increasing its dividend by 3 cents per share, providing further incentive for investors to keep their stocks in XERIS BIOPHARMA.
This move is seen as a sign of confidence for the company’s future prospects, indicating that it believes it will be able to maintain and even improve its financial performance going forward. All in all, XERIS BIOPHARMA had a positive quarter and showed that it is capable of delivering on its financial goals. With its robust portfolio of drugs and confidence-inspiring dividends, investors can expect to see more growth in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Xeris Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 134.07 | -71.44 | -56.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Xeris Biopharma. More…
| Operations | Investing | Financing |
| -80.62 | 34.46 | 127.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Xeris Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 328.78 | 315.14 | 0.22 |
Key Ratios Snapshot
Some of the financial key ratios for Xeris Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 181.8% | – | -42.0% |
| FCF Margin | ROE | ROA |
| -60.7% | -117.2% | -10.7% |
Analysis
At GoodWhale, we conducted an analysis of XERIS BIOPHARMA‘s wellbeing. Based on our Risk Rating, XERIS BIOPHARMA is a medium risk investment in terms of financial and business aspects. After our extensive review, we detected three risk warnings in their balance sheet, cashflow statement, and financial journal. We strongly urge our users to register with us to get more details about the warnings and make an informed decision before investing in XERIS BIOPHARMA. Our platform provides a comprehensive overview of XERIS BIOPHARMA’s financials and business operations and helps users make better-informed decisions. More…
Peers
In the world of pharmaceuticals, there is always competition in terms of who can develop the best and most innovative drugs. This is especially true when it comes to companies like Xeris Biopharma Holdings Inc, which is constantly striving to stay ahead of its competitors. While there are many companies that compete with Xeris Biopharma Holdings Inc, some of the most notable ones include TScan Therapeutics Inc, Soleno Therapeutics Inc, and Milestone Pharmaceuticals Inc.
– TScan Therapeutics Inc ($NASDAQ:TCRX)
TScan Therapeutics Inc. is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment of solid tumors. The company’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors. TScan is also developing TSC-220, a T cell receptor-based therapeutic vaccine targeting the NY-ESO-1 antigen, which is overexpressed in a range of solid tumors.
The company has a market cap of $76.55 million and a return on equity of -44.32%. It is developing novel T cell therapies for the treatment of solid tumors. TScan’s lead product candidate, TSC-100, is a T cell receptor-based therapeutic vaccine targeting the MAGE-A4 antigen, which is overexpressed in a range of solid tumors.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of rare diseases. The company has a market cap of 11.02M as of 2022 and a return on equity of -71.79%. Soleno Therapeutics Inc is headquartered in Redwood City, California.
– Milestone Pharmaceuticals Inc ($NASDAQ:MIST)
Milestone Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company engages in the research, development, and commercialization of cardiovascular products. Its lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation. Milestone Pharmaceuticals Inc was founded by Piotr Wiszniewski and Timothy J. Barberich on March 7, 2005 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc has a market cap of 199.57M as of 2022 and a Return on Equity of -66.21%. The company’s lead product candidate is MSP-2017, a selective adenosine A2a receptor agonist for the treatment of paroxysmal supraventricular tachycardia, including atrial fibrillation.
Summary
Xeris Biopharma reported strong second-quarter financial results for the period ending June 30, 2023. Total revenue increased by 50.2% year-over-year to USD 38.0 million, while net income improved to -19.8 million, a significant improvement from the -26.2 million reported in the prior year.The company’s stock price responded positively to the good news, gaining ground in response to the earnings report. In light of these impressive results, investors should consider adding Xeris Biopharma to their portfolio, as it offers attractive long-term potential. With a strong financial foundation and experienced management team, investing in Xeris Biopharma could be a wise decision.
Related Posts
Recent Posts
